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Abstract
Background. The burden of chronic kidney disease (CKD)
in sub-Saharan Africa is unknown. The aim of this study
was to investigate the prevalence and the risk factors asso-
ciated with CKD in Kinshasa, the capital of the Democratic
Republic of Congo (DRC).
Methods. In a cross-sectional study, 503 adult residents
in 10 of the 35 health zones of Kinshasa were studied
in a randomly selected sample. Glomerular filtration rate
was estimated using the simplified Modification of Diet
in Renal Disease Study equation (eGFR) and compared
with the Cockcroft–Gault equation for creatinine clear-
ance. The associations between health characteristics, indi-
cators of kidney damage (proteinuria) and kidney function
(<60 ml/min/1.73 m2) were examined.
Results. The prevalence of all stages of CKD according to
K/DOQI guidelines was 12.4% [95% confidence interval
(CI), 11.0–15.1%]. By stage, 2% had stage 1 (proteinuria
with normal eGFR), 2.4% had stage 2 (proteinuria with an
eGFR of 60–89 ml/min/1.73 m2), 7.8% had stage 3 (eGFR,
30–59 ml/min/1.73 m2) and 0.2% had stage 5 (eGFR <
15 ml/min/1.73 m2). Hypertension and age were indepen-
dently associated with CKD stage 3. The prevalences of
major non-communicable diseases considered in this study
were 27.6% (95%CI, 25.7–31.3%) for hypertension, 11.7%
(95% CI, 10.3–14.4%) for diabetes mellitus and 14.9%
(95% CI, 13.3–17.9%) for obesity. Hypertension was also
independently associated with proteinuria.
Conclusion. More than 10% of the Kinshasa population
exhibits signs of CKD, which is affecting adults in their
productive years. Risk factors for CKD, including hyper-
tension, diabetes and obesity, are increasing. These alarm-
ing data must guide current and future healthcare policies to
meet the challenge raised by CKD in this city and hopefully
in the whole country.
Correspondence and offprint requests to: Ernest K. Sumaili, Nephrology
Unit, University of Kinshasa, PO Box 123 KIN XI, Democratic Republic
of Congo (DRC)Belgium. Tel:+32-4-366-72-03; Fax:+32-4-366-72-05 ;
E-mail: skiswaya@yahoo.fr
Keywords: chronic kidney disease; diabetes mellitus;
equation (Cockcroft–Gault; MDRD); hypertension;
prevalence
Introduction
Chronic kidney disease (CKD) represents a global public
health problem both in developed and in developing coun-
tries [1]. The prevalence of CKD has been reported mainly
in Western countries. In the USA [2,3], the third National
Health and Nutrition Examination Survey (NHANES III)
estimated that the prevalence of CKD has recently risen
from 11% between 1988 and 1994 up to 13% between 1999
and 2004. The prevalence of CKD is 16% in Australia [4],
10.1% in Singapore [5] and 3.3% in Italy [6]. Almost all the
available data of CKD in developing countries [7,8] come
from individual nephrologists working in tertiary care re-
ferral hospitals. This fact is well illustrated by our recent
report of increasing number of admissions for end-stage re-
nal disease (ESRD) in the Democratic Republic of Congo
(DRC) [8]. Although such observations may probably re-
flect an ascertainment bias [9], nonetheless, severe CKD
is immediately ominous in the DRC and in neighbouring
countries where many affected patients are neither detected
nor properly managed at an early stage [10]. Treatments for
ESRD are prohibitively expensive. Chronic renal failure is
thus a significant cause of death. Earlier interventions for
CKD are likely to be beneficial [1,10]. Unfortunately, the
lack of quantitative knowledge of CKD prevalence hinders
the adoption of appropriate preventive measures that may
be useful. Moreover, traditional cardiovascular risk factors,
such as hypertension and diabetes, are associatedwith CKD
and becoming more common in developing countries. An
estimated 250% increase of the burden of diabetes and car-
diovascular disease is expected by year 2030 in sub-Saharan
Africa [11].Despite these overwhelming facts, CKDhas not
received much attention from health organizations.
In recent years, new guidelines have been published
by the National Kidney Foundation’s Kidney Disease
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Outcomes Quality Initiative (K/DOQI) to help the detec-
tion and management of CKD [12,13]. To the best of our
knowledge, there are no available published data based on
these guidelines from sub-Saharan countries.
We have undertaken this study in order to establish base-
line data on the prevalence of CKD, and other major chronic
non-communicable disease (CND) such as hypertension,
diabetes and obesity in the Congolese population of Kin-
shasa. Socio-demographic features and clinical parameters
were also assessed.
Subjects and methods
Study design and population
The present cross-sectional study is the first part of a larger
ongoing epidemiological survey on CKD and associated
risk factors ‘Pre´valence, de´tection pre´coce et pre´vention des
maladies re´nales chroniques et facteurs de risque associe´s
(PDMRA) en RDC’, carried out between 24 November and
23 December 2006. The selected urban population came
from Kinshasa city, home of ∼7 million people. Ten of its
thirty-five health zones were studied randomly. Because of
the lack of population registries, sampling was adapted to
the administrative organization of the city, which is subdi-
vided into health zones [14].
We used a multistage sampling [15] among the units of
the survey as follows: the health zone (first degree), the
health area (second degree), the street (third degree), the
inhabited parcel (fourth degree) and the household (fifth
degree). Where there were several households in the single
selected parcel, only one household was randomly drawn
and then only one subject ≥20 years old was picked at ran-
dom. The proportion of the participants varied according to
the health zone. This study was approved by the Provincial
Medical Inspection of Kinshasa.
Screening examinations and data collection
Based on the assumption that ∼11% of individuals would
have all stages of CKD, ∼418 subjects were required to
reach this prevalence with the error estimate of 3% [16].
We had planned for 550 subjects but 9% denied partici-
pation. Except for five individuals, no more information
could be drawn from nonresponders. Finally, 503 subjects
were interviewed and examined. Three of them declined
blood testing. The final sample size thus encompassed 500
participants.
All participants provided informed written consent be-
fore enrolment. They were visited twice at home by trained
volunteers who recorded general information on demo-
graphic data, diet, smoking, alcohol consumption, indige-
nous herbal drug use and birth weight knowledge. Data
about family relatives of first degree and medical history
for kidney disease, hypertension, diabetes and current treat-
ment were also recorded. Body weight, height and waist
circumference were measured.
Blood pressure was measured twice in the right or left
arm using a calibrated sphygmomanometer (WelchAllyn,
Germany) at the heart level. Hypertension was defined by a
systolic blood pressure≥140mmHgor diastolic blood pres-
sure ≥90 mmHg (namely unknown hypertensive) and/or
concomitant use of antihypertensive medications by self-
report (known hypertensive) [17].
The body mass index (BMI) was calculated from the
measured height (in metres) and weight (in kilograms) and
categorized as not obese (<25 kg/m2), overweight (25–
29.9 kg/m2) or obese (≥30 kg/m2) according to the 2000
WHO criteria [18].
The diagnosis of diabetes was established after two fast-
ing glucose values of ≥126 mg/dl (namely unknown dia-
betic) using fingertip blood (Accutrend glucometer) and/or
concomitant use of antidiabetic medications by self-report
(known diabetic).
The participants were also asked to collect a urine sample
to detect proteins by the urinary strips ‘Uric 8V’. Female
subjects were instructed to void a random urine specimen,
remote from menstrual periods. Pregnant women were ex-
cluded. Because microalbuminuria and the ratio of albumin
to creatinine (ACR) were not available and urine dipstick
provides only a semi-quantitative estimation of the severity
of proteinuria, kidney damage in stage 1 and 2 CKD in our
study was identified as 24-h urinary protein ≥300 mg per
day.
Serum creatinine and proteinuria were carried out ac-
cording to the kinetic Jaffe (semi-automated polyphotome-
ter, Visual Biome´rieux) and Esbach methods, respectively.
These tests were performed in the laboratory of the Belgian
medical centre of Kinshasa ‘CMK’. For estimated glomeru-
lar filtration rate (eGFR) determination, the abbreviated
equation from the Modification of Diet in Renal Disease
(MDRD) study was used. We have calibrated 35 creatinine
results measured with the Jaffe method against a trace-
able isotope dilution mass spectrometry (IDMS) enzymatic
method (creatinine +, Roche enzymatic diagnostics) at the
UniversityHospital of Lie`ge. Recalibrated serum creatinine
values were thereafter computed for each participant, and
the new MDRD study equation was used for estimation of
the eGFR as 175× (serum creatinine level [mg/dl])−1.154 ×
(age [years])−0.203 [19]. For women and blacks (all patients
in our study), the product of this equation was multiplied
by a correction factor of 0.742 and 1.21, respectively. The
Cockcroft–Gault (CG) estimate of creatinine clearance [20]
was calculated as [(140− age)×weight]/[72× (serum cre-
atinine in mg/dl)] × 1 (or 0.85 if female).
The K/DOQI guidelines [12] for definition and classi-
fication of CKD were used in the present study. In brief,
the CKD stages are defined as follows: stage 1, protein-
uria ≥300 mg per day with an eGFR >90 ml/min/1.73 m2;
stage 2, proteinuria ≥300 mg per day with an eGFR of
60–89 ml/min/1.73 m2; stage 3, an eGFR of 30–59 ml/min/
1.73 m2; stage 4, an eGFR of 15–29 ml/min/1.73 m2 and
stage 5, an eGFR <15 ml/min/1.73 m2.
The term chronic renal failure or CKD 3+ refers to an
eGFR <60 ml/min/1.73 m2. All stages of CKD included
both kidney damage (early stage of CKD, 1 and 2) and
chronic renal failure (CKD 3 or worse).
Statistical analysis
Results are presented as number and percentage or mean ±
SD. Two-sample Student’s t-test and chi-squares were
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used for comparison of means and proportion, where
appropriate.
The participant with an eGFR <30 ml/min/1.73 m2
(n = 1) was excluded from the logistic regression analy-
sis. The outcome under analysis was the presence of CKD,
defined as above. Exposure variables that were considered
included gender, age, smoking, herbal drug use, BMI, dia-
betes mellitus, pulse pressure and hypertension. Categories
of age were divided as follows: 20–39, 40–59, 60–69 and
≥70 years. The crude (unadjusted) relationships between
the exposure variables and the presence or absence of CKD
were examined in univariate logistic regression analyses.
Multivariate stepwise logistic regression analysis was then
done to evaluate the simultaneous effects of various ex-
posure variables, with adjustment for the potential con-
founding effects of other factors. The odds ratio (OR) and
95% confidence intervals were also obtained. The above
approaches were applied separately to the MDRD formula-
based results for CKD stage 3 and for proteinuria. Except
chi-squares, all data analysis and calculations were per-
formed by using the standard statistical package (SPSS
Inc., Chicago, IL, USA; version 10.1). Chi-squares were
made in the dialog box using MedCal version 9.1.01, 2005.
A P-value <0.05 indicated statistical significance.
Results
Characteristics of the study population
The general characteristics of the study population are sum-
marized in Table 1.
Their age ranged between 20 and 79 years (mean 38.6 ±
14.4). There were 206 males and 297 females. A history of
hypertension, diabetes, renal disease, smoking and the use
herbal remedies was recorded in 15.7%, 2%, 0.4%, 10.7%
and 28.0% of participants, respectively.
Prevalence of CKD and associated related risk factors
Table 2 shows the prevalence of CKD. Depending on the
method used to estimate the eGFR, 12.4% (95% CI, 11.0–
15.1%) to 19% (95% CI, 17.3–22.3%) had all stages of
CKD. However, awareness of CKD was very low (3.2%).
According to the MDRD study and CG formulas, 7.8%
(95% CI, 7.6–8.1%) to 15% (95% CI, 13.4–18.1%) had
chronic renal failure (CKD stage 3), respectively. For both
formulas, the ages of patientswithCKDstage 3were similar
(mean 53.9 ± 13 versus 53.6 ± 15.7 years, P > 0.05).
Lower body weight explained some of the higher preva-
lence of CKD stage 3 according to the CG equation. The
prevalence of early stages 1 [2.0%; (95% CI, 1.4–3.1%)]
and 2 [2.4%; (95% CI, 1.8–3.5%)] was almost 10 times
greater than that of stage 5 CKD (0.2%).
Twenty-four-hour quantitative proteinuria of >300 mg/
day was found in 5%.
Stratified by age groups of 20–39, 40–59, 60–69 and
≥70 years, the prevalence of all stages of CKD defined
by the MDRD study formula in the study population was
1.4%, 13.5%, 30.3% and 22.7%, respectively. According
to the CG formula, the prevalence of all stages of CKD,
Table 1. Characteristics of the study population




Age (mean ± SD) (years) 38.6 ± 14.4
Age range (years) 20–79
20–39 (years) 292 58.1
40–59 (years) 156 31.0
60–69 (years) 33 6.6
≥70 (years) 22 4.4
History of hypertension 79 15.7
History of renal disease 2 0.4
Smoking currently or formerly 54 10.4
Herbal remedies use currently 141 28.0
Physical inactivity 40 8.0
Family history of hypertension (first degree) 311 61.8
Family history of diabetes mellitus (first degree) 149 29.6
Values expreesed as number and proportions in parentheses or mean ±
SD, as appropriate.
SD, standard deviation.





n = 500 n = 500
1 10 (2.0) 7 (1.4)
2 12 (2.4) 11 (2.2)
3 39 (7.8) 75 (15.0)
4 0 1 (0.2)
5 1 (0.2) 1 (0.2)
All stages CKD 62 (12.4) 95 (19.0)
CKD 3+ (eGFR
<60 ml/min/1.73 m2)




Proteinuria dipstick (Uric 8V) 90 (18)
Values are number and propotions (%) given in parentheses.
MDRD, Modification of Diet in Renal Disease; CKD, chronic kidney
disease; eGFR, estimated glomerular filtration rate.
stratified by the same age groups, was 5.2%, 18.7%, 57.6%
and 63.6%, respectively (data not shown). From this, there
appears to be a linear rise in rates of CKD with increasing
age in our study population. As illustrated in Figure 1, there
is a distinct overrepresentation of CKD in younger people
in the DRC cohort, in contrast to the US cohort, where
CKD appears to predominate in older, rather than younger
subjects. This difference in distribution is highly significant
for the two middle age ranges 40–59 and 60–69 (P< 0.01).
Risk factors associated with stage 3 CKD and proteinuria
are described in Table 3. In univariate analysis, the risk
factors significantly associatedwith stage 3CKDaccording
to the MDRD study formula were age (unadjusted OR 6.2;
95% CI 2.7–14.3; P < 0.001), hypertension (unadjusted
OR 3.05; 95% CI 1.5–5.9; P < 0.001) and pulse pressure
(unadjusted OR 2.8; 95% CI 1.4–5.6; P < 0.004). On the
other hand, the risk factors significantly associated with
proteinuria were age (unadjusted OR 3.8; 95% CI 1.3–
10.9; P < 0.01), hypertension (unadjusted OR 7.5; 95% CI
3.0–18.4; P < 0.0001) and herbal remedy use (unadjusted
OR 2.9; 95% CI 1.3–6.5; P < 0.01).
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In multivariate analysis, hypertension (adjusted OR 2.1,
95% CI 1.06–4.5; P = 0.03) and age (adjusted OR of 4.2,
for the age range of <65 and ≥65 years, P < 0.001) were
independently associated with CKD stage 3. Hypertension
(adjusted OR 6.8, 95% CI 2.6–17.2; P < 0.001) was also
independently associated with proteinuria.
Prevalence of other CND
The prevalence of hypertension was 27.6% (95% CI, 25.7–
31.3%), and that of diabetes mellitus was 11.7% (95% CI,
10.3–14.4%). There was a 14.9% (95% CI, 13.3–17.9%)
prevalence of obesity (Table 4).
Discussion
Our study documents for the first time the burden of the
CKD in Kinshasa. Using the recommended protocols of the
Kidney Disease Improving Global Outcomes (KDIGO) ini-
tiative [21], CKD in this study averages 12.4–19% depend-
ing on the method used to estimate GFR. The difference
between the prevalence of CKD according to both (MDRD
study versus CG) formulas may probably result from the
Fig. 1. The prevalence of CKD stage 3, according to age range and coun-
try. The data for the USA are taken from Coresh et al. [3]. The width of the
columns is proportional to the percentage of subjects in that age bracket,
by cohort. There is a distinct overrepresentation of CKD in younger peo-
ple in the DRC cohort, in contrast to the USA cohort, where CKD is
more prevalent in older, rather than younger subjects. This difference in
distribution is highly significant for the two middle age ranges (P < 0.01,
chi-square).
Table 4. Prevalences of other major non-communicable diseases in
Kinshasa (DRC)




Diabetes mellitus 59 11.7
Known 10 2.0
Unknown 49 9.7
Overweight (25–29.9 kg/m2) 102 20.3
Obesity (≥30 kg/m2) 75 14.9
Values are number and proportions given in parentheses.
body weight measurement, a variable that is not included
in the MDRD study eGFR equation. Further, the CG equa-
tion was initially developed in Caucasian men. Since the
MDRD study formula has been adequately validated in
African Americans with kidney disease [22], extrapolation
to black Africans appears justified. Hence, we considered
only the results based on the MDRD study formula.
In our survey, roughly one person out of eight is affected
by all stages of CKD.
This value is higher than the 3.3% found in Italy [6],
similar to 12.7% in Norway [23], but lower than the value
of 16% in Singapore [4]. Comparisons between studies are
of course fraught with difficulty as the definitions and the
criteria of selection may substantially differ. Nonetheless,
our results are similar to those recently reported by Coresh
et al. in the USA [3]. Yet when one considers the increasing
prevalence of known and unknown risk factors for CKD,
it appears likely that in Kinshasa, the occurrence of CKD
stage 3 or worse will increase to rates beyond those in the
USA. Moreover, had we used the spot microalbuminuria or
ACR, the prevalence of CKD at the early stage (1 and 2)
would probably be even higher in the DRC cohort.
The higher CKD prevalence observed in middle-aged
adults in the DRC compared to the USA is not due to
the presence of only black Africans in our cohort. That is
because the CKD prevalence data for NHANES III show
a lower prevalence of CKD in blacks compared to whites
[3]. The greater prevalence of CKD in black adults aged
<70 years in Kinshasa compared to that in the USA may
have specific causes that require closer scrutiny.
Table 3. Odds ratio of risk factors associated with CKD (univariate and multivariate analysis) in Kinshasa
Risk factors OR (univariate 95% CI P-value OR (multivariate 95% CI P-value
analysis) analysis)
CKD stage 3 (MDRD study)
Hypertension versus no 3.05 1.5–5.9 0.001 2.1 1.06–4.5 0.03
Pulse Pressure >60 mmHg versus <60 mmHg 2.8 1.4–5.6 0.004 1.2 0.4–3.1 0.6
≥65 years versus <65 years 6.2 2.7–14.3 <0.001 4.2 1.7–10.4 0.001
24-h quantitative proteinuria
(>300 mg/24 h)
Hypertension versus no 7.5 3.0–18.4 <0.001 6.8 2.6–17.2 <0.001
≥65 years versus <65 years 3.8 1.3–10.9 0.01 1.6 0.5–5.0 0.3
Herbal remedies use 2.9 1.3–6.5 0.009 2.2 0.8–5.6 0.07
OR, odds ratio; MDRD, Modification of Diet in Renal Disease; CI, confidence interval; CKD, chronic kidney disease; PP, pulse pressure.
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In this survey, we found a very low occurrence rate of
ESRD. This is not in contradiction to our finding of a high
rate of CKD in this city. That is because the prevalence of
ESRD is influenced by both the number of new patients
requiring renal replacement therapy (RRT) (incidence) and
the number of deaths. Indeed, incidence reflects typically
the interaction of genetic and environmental factors as well
as the efficacy of primary health care services, while mor-
tality depends on the availability of RRT [24].
Many people with ESRD in the DRC die of uraemia be-
cause only a few of them can afford peritoneal dialysis as
the RRT available in that country [8,10]. In addition, those
patients who do not progress to ESRD had an increased risk
of death from cerebrovascular and heart disease. Another
potential explanation for high rates of CKD compared to
ESRD would be the slowing of CKD so that people do not
reach ESRD as reported in Norway by Hallan et al. [23].
However, such is not the case in DRC, where recent expe-
rience [25] in secondary healthcare reveals that many Con-
golese patients are neither detected nor adequatelymanaged
at an early stage and are not referred to the sole renal unit
existing in this country.
Among several possible explanations for the higher
prevalence of CKD in Kinshasa, we can suggest genetic,
intrauterine, economic and manpower factors. Although
most of our study population did not have birth certificates
or knowledge of weight at birth, it is known that low birth
weight (LBW) is common in Africa, as it is among African
Americans [26]. An additional explanation for CKD in the
DRC is the increased burden of CND (such as hypertension,
diabetes, obesity) and the persistence of poverty-related
diseases (malaria, tuberculosis, HIV infection and the cur-
rent resurgence of leprosy, trypanosomiasis, filariosis and
schistosomiasis), all factors playing an important role in
the development of kidney diseases [8,24]. But this study
did not address the specific causes of CKD in individual
subjects. Also, appropriate management of these patients is
adversely impacted by economic problems in general and
civil war and lack of manpower in particular [7,10].
As expected [2,3], hypertension and age were indepen-
dently associated with CKD. Hypertension is injurious to
the kidney and leads to renal disease. Hypertension is also
a common pathway of renal disease for which it is hard to
distinguish between cause and end result [27].
Ageing is well known as a risk factor for CKD. But
subjects with CKD in the present study are relatively young,
as has been noted in most developing countries [7,8]. In
contrast, the USDRS [28] and the NHANES III [2,3] data
show that CKD or ESRD in the USA is strikingly a disease
of older people. This difference in distribution is highly
significant mainly for the two middle age ranges. This has
distinct economic effects, because CKD can thus cause
death or disability to wage earners in the DRC.
The cause for this discrepancy remains unknown, but
might be due to different risk factors leading to CKD or
to the different population age distribution of the sample
geographical area. For example, themore developed regions
show much higher proportions of persons aged 65 years or
more, these older people being as much as one-fifth of the
population. In less-developed parts of the world, <10% of
the population is in the >65 age range [29]. Nonetheless,
because the difference of the CKD prevalence in the middle
age groups in the DRC compared to that in the USA is a
percentage, and not an absolute number, it may not merely
depend on a difference in the population pyramid.
Another preventable risk factor for CKD is the use of
herbal remedies, which was found in this survey in uni-
variate analysis but not in multivariate analysis. Several
compelling studies [30,31] demonstrated renal toxicity and
other adverse effects of traditional herbal remedies. Fur-
ther, histopathological and toxicological studies are recom-
mended in order to establish the causal relationship and
specific component(s) of the culprit products.
Another important finding of this study is the determina-
tion of the real extent of the major CND such as hyperten-
sion, diabetes and obesity. These are possibly modifiable
risk factors for CKD. Indeed, the prevalence of hyperten-
sion in our study was as high as 27.6% and similar to the
prevalence of 28.3% found in Ghana [32]. These values
are much higher than the 14% reported previously in this
country by M’Buyamba in 1987 [33] and in Nigeria as well
as 16.9% in Cameroon [34], but a bit lower than the value
of 32.6% for blacks in the USA [34].
One of the consequences of adoption of a Western
lifestyle in Africa is an increased prevalence of hyperten-
sion from past historical levels when these levels were prob-
ably much lower. It has been estimated that cardiovascular
disease will become the leading global cause of death and
disability in the very near future [11].
Over the past 40 years, the prevalence of diabetes has
also increased significantly in Kinshasa.
According to the epidemiological study of the 1960s, the
proportion of diabetes among hospital patients was 0.012%.
It was 7% in another epidemiologic survey in 2000 [35]
and it is now 11.7% in our study. At the same time, the
prevalence of obesity has increased from 9% in 2000 [35]
to 14.9% at present. This increasing prevalence of diabetes
and of obesity will probably impact on future rates of CKD
in the DRC.
However, some limitations exist in this study: it is cross-
sectional with only one measure (for serum creatinine, pro-
teinuria and blood pressure), it has a relatively small size
and it relies on both MDRD study and CG equations, the
validation ofwhich is lacking among theAfrican population
as well as in the non-CKD population [36].
Despite possible methodological limitations, this study
emphasizes that CKD and associated risk factors such as
hypertension, diabetes and obesity are highly prevalent in
Kinshasa, while awareness of renal disease is very low.
This work confirms hypertension and age as significant
CKD risk factors. However, large prospective studies in
this country are needed to improve the precision of these
preliminary data and so to develop adapted preventive
strategies.
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